SIMON CHERRY, UC Davis

Total body PET

Simon Cherry

Simon Cherry develops novel technologies and methods for quantitative biomedical imaging. The Cherry Lab focuses on molecular imaging using positron emission tomography (PET) scanning; in particular developing faster and more sensitive detection technologies. The laboratory has developed technologies with widespread applications for improving diagnosis, stratifying patients for treatment and assessing response to that treatment. The team is currently studying pathologic processes that involve multiple organs systems or the entire body. Cherry co-leads the EXPLORER project, a collaboration with several colleagues to develop the world’s first total-body PET scanner.

Read more about his work here

VALENTINA EMILIANI, Paris

The use of wave-front shaping for neuroscience

Valentina Emiliani

Valentina Emiliani’s lab has pioneered the use of wave-front shaping for neuroscience. In particular, they demonstrated a number of new techniques for 3D optogenetics neural control, techniques based on computer generated holography, generalized phase contrast and temporal focusing. Most of these systems are currently the only existing worldwide. With these approaches, this lab first demonstrated simultaneous 2P optogenetics stimulation of multiple cell, all optical neuronal control at cellular resolution in freely moving mice, and 3D neuronal circuits manipulation with sub-millisecond temporal precision and single cell resolution. These approaches are currently used in a series of collaborative projects, including the analysis of Zebrafish swim circuit, the investigation of short term memory, the study of calcium dynamics in respiratory-related neurons, the investigation of the pathophysiology of the visual system, the investigation of retinal circuits and the optical detection of neuronal membrane voltage.mmunology.

Read more about her work here

AXEL MONTAGNE, Edinburgh

Evidence for neuromorphological coupling in rapid-onset ultrafast diffusion MRI signals

Axel Montagne

Axel Montagne’s career has been focusing on how cerebrovascular dysfunctions contribute to neurodegeneration and dementia in both animal models and humans. He combines molecular approaches with rodent non-invasive imaging, particularly MRI, PET and two-photon microscopy, to study the causes and effects of blood-brain barrier (BBB) dysfunction. His group aims to understand how, when, and where endothelial cells and pericytes lining the blood-brain barrier become dysfunctional in the early stages of age-related cognitive decline using cutting-edge brain imaging technology. The ultimate goal is to develop precise treatments targeting brain vasculature to protect brain functions.

Read more about his work here